- Amedis Pharmaceuticals Ltd (2000 - 2002). Founder and CSO of chemistry-based drug discovery company with combined lab and software platform. Lead team raising £4M Series A, recruited CEO, COO, management team. Amedis was sold in 2005.
- Delta G. Ltd (2002 - 2008). Founder and CEO of drug discovery company in anti-cancer biology. Raised seed funding and directed initial programmes, lead IP development.
- Karus Therapeutics (2005 - 2012). University spin-out, founded 2005. Founding director of drug discovery company, on the Board through CEO recruitment, several Angel rounds raising £3.2M and first £20M VC round.
- Glythera Ltd. (2008 - 2014). University spin-out, founded 2007. Supported the company through initial growth, IP development, recruitment of key staff, move of facilities and securing £2M Series A.
- Five Alarm Bio (2016 - ). Founder and CSO of new start-up in anti-aging therapeutics. Defined company strategy, identified initial IP, managed research programme for ab inito start-up.
|
- A University research group spin-out. The academic group had identified new science in protein engineering, and had ambitions to develop this into a therapeutic product. I supported IP development, market identification and business model development, writing a business plan, and supported initial approaches to fundraisers.
- A government biotechnology strategy. With others, I helped the Government of Malta define Malta's areas of research excellence, synergies with neighbouring country's research strengths, and formulate a collaboration strategy for the Government.
- For a national development agency. I evaluated the potential commercial path for a Synthetic Biology technology, identifying possible business models, funding routes, and the likely market need in a rapidly changing, cutting edge technology.
- For a Russian investment group. I reviewed an investment strategy document, and critiqued it in light of European and American investment trends in early stage investing and its successes and failures.
- A UK University technology. I developed business models for a novel chemical synthetic technology from a leading UK University, including spin-out, licence and contract options, and supported the academic's initial market research, contract negotiation and investment pitching.
- For a Department in a leading UK University. I identified the research strengths and weaknesses, global competitive position, and fit to research strengths of potential merger partners.
|
